Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors

Oncology Nursing Forum

Volumn 40, Issue 6, 2013, Pages 549-557

  Swenson, Karen K ^a,b   Nissen, Mary Jo ^a   Henly, Susan J ^c   Maybon, Laura ^a   Pupkes, Jean ^d   Zwicky, Karen ^a   Tsai, Michaela L ^e   Shapiro, Alice C ^a  

^a PARK NICOLLET INSTITUTE   (United States)

^b Virginia Piper Cancer Institute   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d NORTH MEMORIAL MEDICAL CENTER   (United States)

^e Minnesota Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ESTROGEN;

ADJUVANT CHEMOTHERAPY; AGED; ARTHRALGIA; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DAILY LIFE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MUSCLE WEAKNESS; MYALGIA; NEOPLASM; PAGET NIPPLE DISEASE; PAIN ASSESSMENT; POSTMENOPAUSE; PROSPECTIVE STUDY; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; TREATMENT OUTCOME; WALKING DIFFICULTY;

ACTIVITIES OF DAILY LIVING; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; MOBILITY LIMITATION; MUSCLE WEAKNESS; MYALGIA; NEOPLASMS, HORMONE-DEPENDENT; PAIN MEASUREMENT; POSTMENOPAUSE; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 84893031211     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/13.ONF.549-557     Document Type: Article

References (55)

1. Allen, K.D., DeVellis, R.F., Renner, J.B., Kraus, V.B., & Jordan, J.M. (2007). Validity and factor structure of the AUSCAN Osteoarthritis Hand Index in a community-based sample. Osteoarthritis and Cartilage, 15, 830-836.
2. American Cancer Society. (2013). Cancer facts and figures, 2013. Atlanta, GA: Author.
3. Anderson, W.F., Katki, H.A., & Rosenberg, P.S. (2011). Incidence of breast cancer in the United States: Current and future trends. Journal of the National Cancer Institute, 103, 1397-1402.
4. Bellamy, N. (2005). The WOMAC Knee and Hip Osteoarthritis Indices: Development, validation, globalization, and influence on the development of the AUSCAN Hand Osteoarthritis Indices. Clinical and Experimental Rheumatology, 23(5, Suppl. 39), S148-S153.
5. Bellamy, N., Sothern, R.B., Campbell, J., & Buchanan, W.W. (2002). Rhythmic variations in pain, stiffness, and manual dexterity in hand osteoarthritis. Annals of the Rheumatic Diseases, 61, 1075-1080.
6. Briot, K., Tubiana-Hulin, M., Bastit, L., Kloos, I., & Roux, C. (2010). Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: The ATOLL (articular tolerance of letrozole) study. Breast Cancer Research and Treatment, 120, 127-134.
7. Broderick, J.E., Schneider, S., Junghaenel, D.U., Schwartz, J.E., & Stone, A.A. (2013). Validity and reliability of patient-reported outcomes measurement information system instruments in osteoarthritis. Arthritis Care Research, 65, 1623-1633. doi:10.1002/acr.22025
8. Carlson, R.W., Allred, D.C., Anderson, B.O., Burstein, H.J., Carter, W.B., Edge, S.B., Zellars, R. (2011). Invasive breast cancer. Journal of the National Comprehensive Cancer Network, 9, 136-222.
9. Coates, A., Keshaviah, A., Thurlimann, B., Mouridsen, H., Mauriac, L., Forbes, J., Goldhirsch, A. (2007). Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. Journal of Clinical Oncology, 25, 486-492.
10. Cohen, J. (1977). Statistical power analysis for the behavioral sciences (revised ed.). New York, NY: Academic Press.
11. Coleman, R.E., Bolten, W.W., Lansdown, M., Dale, S., Jackisch, C., Merkel, D., Hadji, P. (2008). Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations. Cancer Treatment Reviews, 34, 275-282. doi:10.1016/j.ctrv.2007.10.004
12. Coombes, R.C., Hall, E., Gibson, L.J., Paridaens, R., Jassem, J., Delozier, T., van de Velde, C. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine, 350, 1081-1092.
13. Crew, K.D., Capodice, J.L., Greenlee, H., Brafman, L., Fuentes, D., Awad, D., Hershman, D.L. (2010). Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. Journal of Clinical Oncology, 28, 1154-1160.
14. Crew, K.D., Greenlee, H., Capodice, J., Raptis, G., Brafman, L., Fuentes, D., Hershman, D.L. (2007). Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. Journal of Clinical Oncology, 25, 3877-3883.
15. Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J.F. (2010). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncology, 11, 1135-1141.
16. Davidson, B., Vogel, V., & Wickerham, L. (2007). Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: Results of a linguistic study focusing on adherence and persistence to therapy. Journal of Supportive Oncology, 5, 139-143.
17. Day, R., Ganz, P.A., Costantino, J.P., Cronin, W.M., Wickerham, D.L., & Fisher, B. (1999). Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of Clinical Oncology, 17, 2659-2669.
18. Dodd, M., Janson, S., Facione, N., Faucett, J., Froelicher, E.S., Humphreys, J., Taylor, D. (2001). Advancing the science of symptom management. Journal of Advanced Nursing, 33, 668-676.
19. Early Breast Cancer Trialists' Collaborative Group. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet, 365, 1687-1717. doi:10.1016/S0140-6736(05)66544-0
20. Fallowfield, L., Atkins, L., Catt, S., Cox, A., Coxon, C., Langridge, C., Price, M. (2006). Patients' preference for administration of endocrine treatments by injection or tablets: Results from a study of women with breast cancer. Annals of Oncology, 17, 205-210.
21. Fries, J.F., Cella, D., Rose, M., Krishnan, E., & Bruce, B. (2009). Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing. Journal of Rheumatology, 36, 2061-2066.
22. Gaillard, S., & Stearns, V. (2011). Aromatase inhibitor-associated bone and musculoskeletal effects: New evidence defining etiology and strategies for management. Breast Cancer Research, 13, 205.
23. Gallicchio, L., Macdonald, R., Wood, B., Rushovich, E., & Helzlsouer, K. (2011). Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy. Breast Cancer Research and Treatment, 130, 569-577. doi:10.1007/s10549-011-1611-2
24. Ganz, P.A., Greendale, G.A., Petersen, L., Zibecchi, L., Kahn, B., & Belin, T.R. (2000). Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial. Journal of the National Cancer Institute, 92, 1054-1064. doi:10.1093/jnci/92.13.1054
25. Glass, A.G., Lacey, J.V., Jr., Carreon, J.D., & Hoover, R.N. (2007). Breast cancer incidence, 1980-2006: Combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. Journal of the National Cancer Institute, 99, 1152-1161.
26. Gummesson, C., Ward, M., & Atroshi, I. (2006). The shortened disabilities of the arm, shoulder and hand questionnaire (QuickDASH): Validity and reliability based on responses within the full-length DASH. BMC Musculoskeletal Disorders, 7, 44.
27. Henry, N.L., Azzouz, F., Desta, Z., Li, L., Nguyen, A.T., Lemler, S., Storniolo, A.M. (2012). Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. Journal of Clinical Oncology, 30, 936-942.
28. Henry, N.L., Banerjee, M., Wicha, M., Van Poznak, C., Smerage, J.B., Schott, A.F., Hayes, D.F. (2011). Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer, 117, 5469-5475. doi:10.1002/cncr.26230
29. Henry, N.L., Giles, J.T., & Stearns, V. (2008). Aromatase inhibitor-associated musculoskeletal symptoms: Etiology and strategies for management. Oncology, 22, 1401-1408.
30. Hudak, P.L., Amadio, P.C., & Bombardier, C. (1996). Development of an upper extremity outcome measure: The DASH (disabilities of the arm, shoulder, and hand) [corrected]. The Upper Extremity Collaborative Group (UECG). American Journal of Industrial Medicine, 29, 602-608.
31. Husted, J.A., Cook, R.J., Farewell, V.T., & Gladman, D.D. (2000). Methods for assessing responsiveness: A critical review and recommendations. Journal of Clinical Epidemiology, 53, 459-468.
32. Kanematsu, M., Morimoto, M., Honda, J., Nagao, T., Nakagawa, M., Takahashi, M., Sasa, M. (2011). The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia. BMC Cancer, 11, 436.
33. Khan, Q.J., O'Dea, A.P., & Sharma, P. (2010). Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. Journal of Oncology, 2010, 654348. doi:10.1155/2010/654348
34. Khan, Q.J., Reddy, P.S., Kimler, B.F., Sharma, P., Baxa, S.E., O'Dea, A.P., Fabian, C.J. (2010). Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Research and Treatment, 119, 111-118.
35. Kubo, M., Onishi, H., Kuroki, S., Okido, M., Shimada, K., Yokohata, K., Katano, M. (2012). Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Research, 32, 2331-2336.
36. Leblanc, M., Mao, J.J., Stineman, M. Demichele, A., & Stricker, C. (2013). Validation of QuickDASH outcome measure in breast cancer survivors for upper extremity disability. Archives of Physical Medication and Rehabilitation. Advance online exclusive.
37. Liang, M.H. (2000). Longitudinal construct validity: Establishment of clinical meaning in patient evaluative instruments. Medical Care, 38(9, Suppl.), II84-II90. doi:10.1097/00005650-200009002-00013
38. Liang, M.H., Fossel, A.H., & Larson, M.G. (1990). Comparisons of five health status instruments for orthopedic evaluation. Medical Care, 28, 632-642. doi:10.1097/00005650-199007000-00008
39. Lintermans, A., Van Calster, B., Van Hoydonck, M., Pans, S., Verhaeghe, J., Westhovens, R., Neven, P. (2011). Aromatase inhibitor-induced loss of grip strength is body mass index dependent: Hypothesis-generating findings for its pathogenesis. Annals of Oncology, 22, 1763-1769. doi:10.1093/annonc/mdq699
40. Love, S.M. (2005). Dr. Susan Love's breast cancer book (4th ed.). Cambridge, MA: Da Capo Lifelong Press.
41. Mao, J.J., Stricker, C., Bruner, D., Xie, S., Bowman, M.A., Farrar, J.T., DeMichele, A. (2009). Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer, 115, 3631-3639. doi:10.1002/cncr.24419
42. Mathias, S., Nayak, U.S., & Isaacs, B. (1986). Balance in elderly patients: The "get up and go" test. Archives of Physical Medicine and Rehabilitation, 67, 387-389.
43. Mathiowetz, V., Kashman, N., Volland, G., Weber, K., Dowe, M., & Rogers, S. (1985). Grip and pinch strength: Normative data for adults. Archives of Physical Medicine and Rehabilitation, 66(2), 69-74.
44. Mathiowetz, V., Weber, K., Volland, G., & Kashman, N. (1984). Reliability and validity of grip and pinch strength evaluations. Journal of Hand Surgery, 9, 222-226.
45. Morales, L., Pans, S., Verschueren, K., Van Calster, B., Paridaens, R., Westhovens, R., Neven, P. (2008). Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. Journal of Clinical Oncology, 26, 3147-3152. doi:10.1200/JCO.2007.15.4005
46. Muslimani, A.A., Spiro, T.P., Chaudhry, A.A., Taylor, H.C., Jaiyesimi, I., & Daw, H.A. (2009). Aromatase inhibitor-related musculoskeletal symptoms: Is preventing osteoporosis the key to eliminating these symptoms? Clinical Breast Cancer, 9(1), 34-38.
47. National Comprehensive Cancer Network. (2013). NCCN Clinical Practice Guidelines in Oncology: Breast cancer [v.3.2013]. Retrieved from www.nccn.org/professionals/physician-gls/pdf/breast.pdf
48. Podsiadlo, D., & Richardson, S. (1991). The timed "Up & Go": A test of basic functional mobility for frail elderly persons. Journal of the American Geriatrics Society, 39, 142-148.
49. Presant, C.A., Bosserman, L., Young, T., Vakil, M., Horns, R., Upadhyaya, G., Howard, F. (2007). Aromatase inhibitor-associated arthralgia and/or bone pain: Frequency and characterization in non-clinical trial patients. Clinical Breast Cancer, 7, 775-778.
50. Rajotte, E.J., Yi, J.C., Baker, K.S., Gregerson, L., Leiserowitz, A., & Syrjala, K.L. (2012). Community-based exercise program effectiveness and safety for cancer survivors. Journal of Cancer Survivorship, 6, 219-228. doi:10.1007/s11764-011-0213-7
51. Serlin, R.C., Mendoza, T.R., Nakamura, Y., Edwards, K.R., & Cleeland, C.S. (1995). When is cancer pain mild, moderate, or severe? Grading pain severity by its interference with function. Pain, 61, 277-284.
52. Stanton, A.L., Bernaards, C.A., & Ganz, P.A. (2005). The BCPT symptom scales: A measure of physical symptoms for women diagnosed with or at risk for breast cancer. Journal of the National Cancer Institute, 97, 448-456. doi:10.1093/jnci/dji069
53. Terwee, C.B., Dekker, F.W., Wiersinga, W.M., Prummel, M.F., & Bossuyt, P.M.M. (2003). On assessing responsiveness of health-related quality-of-life instruments: Guidelines for instrument evaluation. Quality of Life Research, 12, 349-362. doi:10.1023/A:1023499322593
54. Winters-Stone, K.M., Schwartz, A.L., Hayes, S.C., Fabian, C.J., & Campbell, K.L. (2012). A prospective model of care for breast cancer rehabilitation: Bone health and arthralgias. Cancer, 118(8, Suppl.), 2288-2299.
55. Zhang, Q., Tang, D., & Zhao, H. (2010). Immunological therapies can relieve aromatase inhibitor-related joint symptoms in breast cancer survivors. American Journal of Clinical Oncology, 33, 557-560.